These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 26876383)

  • 1. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
    Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
    Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy.
    Busch M; Rüster C; Schinköthe C; Gerth J; Wolf G
    Clin Nephrol; 2013 Aug; 80(2):105-13. PubMed ID: 23587125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.
    Fervenza FC; Abraham RS; Erickson SB; Irazabal MV; Eirin A; Specks U; Nachman PH; Bergstralh EJ; Leung N; Cosio FG; Hogan MC; Dillon JJ; Hickson LJ; Li X; Cattran DC;
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2188-98. PubMed ID: 20705965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
    Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
    Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
    Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
    Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.
    Irazabal MV; Eirin A; Lieske J; Beck LH; Sethi S; Borland TM; Dillon JJ; Nachman PH; Nasr SH; Cornell LD; Leung N; Cattran DC; Fervenza FC
    Nephrol Dial Transplant; 2013 Jan; 28(1):137-46. PubMed ID: 22987142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis.
    Zou PM; Li H; Cai JF; Chen ZJ; Li C; Li XW
    Chin Med Sci J; 2018 Mar; 33(1):9-19. PubMed ID: 29620510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
    van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
    J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
    Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
    Front Immunol; 2021; 12():738788. PubMed ID: 34721403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
    Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
    BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine treatment in idiopathic membranous nephropathy nephrotic syndrome in adults: a retrospective study spanning 15 years.
    Tao JL; Liu LL; Wen YB; Gao RT; Li H; Li MX; Li XM; Li XW
    Chin Med J (Engl); 2011 Nov; 124(21):3490-4. PubMed ID: 22340164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
    Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
    Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
    Yan P; Fang X; Ke B
    Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
    Hogan J; Godron A; Baudouin V; Kwon T; Harambat J; Deschênes G; Niel O
    Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.
    Rosenzwajg M; Languille E; Debiec H; Hygino J; Dahan K; Simon T; Klatzmann D; Ronco P
    Kidney Int; 2017 Jul; 92(1):227-237. PubMed ID: 28318628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
    Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
    Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of the therapeutic approach to membranous nephropathy.
    Ponticelli C; Patrizia P; Del Vecchio L; Locatelli F
    Nephrol Dial Transplant; 2021 Apr; 36(5):768-773. PubMed ID: 32206786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.